RandallFlagg You have missed the objective of the UK study...

RandallFlagg

You have missed the objective of the UK study completely and what answers the NHS is actually looking for .Firstly Wheezo is reimbursed in the US, by for profit Health Insurance companies who are tougher than Government institutions to get money out of. They have allocated a monetary value and codes for remote patient monitoring. So in the US there is no question whether Wheezo works or is their a health benefit in monitoring wheeze and associated triggers as a marker of asthma severity. The UK study is taking a multi factorial, holistic approach using multiple interventions - medication, Wheezo, smart inhaler to ensure patients are taking their medication properly, how often are they being followed up by their doctor, ability to share data with health care professionals in real time instead of writing it on a piece of paper etc, etc...and comparing that to today's practice (real world) that is failing miserably and costing the Healthcare system billions. Best case scenario will be a new protocol to manage paediatric asthma using this holistic approach of multiple interventions with Wheezo being a key component of remote daily monitoring and data capture. The study will provide real health outcomes data that can be quantified and the value of a technology like Wheezo in reducing unnecessary doctor visits , emergency room & hospital admissions can be quantified - let alone maybe save a life! That's when the company can negotiate a fair price with the NHS. The fact Wheezo was chosen to be part of optimal care to be tested against today's best practice is already a major win.